CMD: Dr Bharat Daftary
Value Enhancer in Biotech
Bharat Serums has increased its sales marginally, by 1.6 percent, during 2004-05
Bharat Serums and Vaccines Ltd (BSV) has marginally increased it biotechnology sales in 2004-05 to Rs 81 crore from last year's sales of Rs 79.68 crore.
The sales from its biotech/biological products for the year 2004-05 has registered a growth of just 1.65 percent to Rs 81 crore over last year's sale of Rs 79.68 crore. For the year 2002-03, its sales stood at Rs 72.37 crore. The company has been doing well in terms of its financial results by improving its sales from Rs 46.41 crore in 2000-01 and Rs 57.34 crore in 2001-02. In 2003–04, it introduced streptokinase, urokinase, and low molecular weight heparin, anti-rabies serum and anti-thymocyte globulin.
Bharat Serums and Vaccines is a company floated by Dr Vinod G Daftary .The BSV has significant R&D activities with a focus on biopharmaceuticals, novel drug delivery systems and equine products. BSV is one of the fast growing pharmaceutical companies in India with a CAGR of more than 50 percent in the last three years It has developed its competency in the areas of NDDS and in development and purification of equine-based therapeutic products.
Since its inception in 1971, BSV has worked ceaselessly to research, develop, manufacture and market specialized biological, pharmaceutical and biotechnology products. Its product portfolio comprises of a wide range of products such as plasma derivatives, monoclonals, hormones, equine antitoxins and serums, antifungals, anaesthetics, cardiovascular and diagnostic products.
Bharat Serums and Vaccines is investing about seven percent of its total revenue in R&D infrastructure including high quality laboratory facilities, experienced research scientists and personnel. The R&D activities have been granted recognition by the Department of Scientific and Industrial Research. The University of Bombay has also granted recognition to its R & D laboratory as a center for Postgraduate and Doctoral research in Microbiology, Applied Biology and Biochemistry. It also got the approval and accreditations from WHO and DGCI to manufacture pharmaceutical products.
BSV has distinct R&D divisions working extensively on new drug delivery systems and biotechnology. The thrust of the R&D in the previous years has been on novel drug delivery systems (especially injectibles) in the areas of anaesthesia, anti- fungals and oncology. On biotechnology front the team has been working on developing new generation recombinant therapeutics that replaces the traditional plasma products, which are in short supply worldwide due to the dependence on human donors, and runs the risk of viral infections like HIV etc.
BSV manufactures and markets plasma, pharma and biotechnology products. It was primarily set up to export plasma derivatives to US, Europe and Japan. Today, BSV has developed considerable market strengths in the domestic markets through its portfolio of niche primary line, life-saving injectibles. It remains focused on ascending the value chain in the manufacturing and marketing of biological, pharmaceutical and biotechnology products and is committed to enhancing the sales of these products. BSV has in its portfolio over 25 brands, most of them having the potential of being a product capable of being marketed in the global market. Exports would continue to propel its growth in the coming years.
The group has promoted ventures in clinical research, diagnostics and therapeutic enzymes through other associate ventures.